Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)

Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the absence of targeted, mechanism-based therapies. As a result, it is difficult to achieve adequate analgesia in all patients despite the extensive armamentarium of inexpensive generic therapies. No truly novel analgesic solutions for chronic pain have launched in recent years, but the pain pipeline is active and diverse, driven by the unmet clinical need and opportunity for better analgesics. Developers of emerging agents will benefit from a granular understanding of current treatment patterns in this large, underserved patient population.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CBP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CBP patients?
• How has Jourvnax been integrated into the treatment algorithm, and what is its source of business?
• What percentage of CBP patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of CBP patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: NSAIDs, celecoxib, benzodiazepines, gabapentin, pregabalin, tizanidine, corticosteroids, opioids, dual-acting opioids, duloxetine

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses.

Key analyses

• Brand / therapy usage across longitudinal patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Combination therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flow charts.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.